Postdoc Tom Schulz represented the lab at the 2026 Biological Engineering Retreat, describing our efforts to expand the repertoire of druggable targets, emphasizing oncology. He discussed various strategies to target so-called ‘undruggable’ oncogenic drivers and crucial druggable partners, including kinases. Thanks to Tom for representing the team!
TOM SCHULZ at the 2026 BE retreat
The Koehler Lab aims to innovate in the earliest stages of drug discovery by building chemical tools or technologies to assist in the process of target validation and by expanding the repertoire of protein targets that are considered to be druggable. We focus primarily on building chemical tools and methods for studying temporal aspects of transcriptional regulation in development and disease with a focus on cancer.
The Koehler Lab is supported through the generosity of our public and private funding partners.
We will gladly accommodate requests for greater accessibility of public content.
